Kindeva Drug Delivery

Executive Summary

Kindeva Drug Delivery is a UK-based Contract Development and Manufacturing Organization (CDMO) with a rich history dating back to 1956, specializing in drug-device combination products for injectable, inhalation, and dermal delivery. The company offers end-to-end services, from early-stage development to commercial manufacturing, leveraging deep expertise in complex drug delivery technologies. Kindeva's purpose-driven approach focuses on advancing patient care and sustainability, positioning it as a trusted partner for pharmaceutical companies seeking to accelerate their product pipelines. With a strong legacy and a dedicated team, Kindeva continues to innovate in the rapidly growing drug delivery market, which is driven by the increasing demand for biologics, self-administration devices, and combination products. As a private CDMO, Kindeva benefits from long-term relationships with major pharma clients and a robust pipeline of programs. The company's strategic investments in capacity expansion and technology platforms, such as its proprietary inhalation and injectable systems, are expected to drive revenue growth. While financial details are not publicly disclosed, the CDMO sector has seen strong tailwinds from outsourcing trends and complex drug formulations. Kindeva's ability to support both early-stage and commercial-scale projects gives it a competitive edge. The company's focus on sustainability and patient-centric solutions further enhances its value proposition in an industry increasingly emphasizing environmental responsibility.

Upcoming Catalysts (preview)

• Q2 2026Completion of new manufacturing facility expansion in Loughborough85% success
• Q4 2026Signing of a major contract with a top-20 pharma for inhalation therapy50% success
• Q1 2027Launch of next-generation injectable device platform60% success